BSX stock sentiment todayBoston Scientific Corporation
Sentiment verdict
Gossip first, financials second — HOT at 88% confidence.
Last updated · cached analysis, refreshes periodically
BSX
Boston Scientific CorporationBoston Scientific is a premium-growth medtech powerhouse currently capturing significant market share in the high-growth Electrophysiology and Structural Heart segments.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for BSX. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the massive success of the FARAPULSE PFA system, which is disrupting the atrial fibrillation market and driving double-digit organic growth that outpaces the broader medtech sector.
- ·Rapid adoption of Pulsed Field Ablation (PFA) technology
- ·Market share gains in the cardiology and peripheral interventions segments
- ·Strong execution on the '2024-2026' long-term financial goals
- ·M&A momentum following the Silk Road Medical acquisition
Financial
BSX consistently delivers top-tier organic revenue growth (14-15% recently) and disciplined margin expansion, though it carries a valuation premium compared to legacy medtech peers.
- ·High teens adjusted EPS growth trajectory
- ·Expanding operating margins toward 27%+
- ·Robust R&D spend at ~10-12% of revenue
- ·Strong free cash flow supporting strategic tuck-in acquisitions
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·Insiders bought a net $9.5M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High P/E multiple leaves little room for earnings misses
- ·Increased competition in the PFA space from Medtronic and Johnson & Johnson
- ·Potential regulatory or reimbursement hurdles for new cardiovascular devices
Peer temperature
How direct competitors stack up against BSX right now.
- NEUTRALMDTMedtronic plc
COLDER — while offering a higher dividend, MDT lacks the hyper-growth cardiovascular catalysts of BSX and is struggling with slower legacy business segments.
See full analysis → - HOTABTAbbott Laboratories
NEUTRAL — trading at a similar premium but offers more diversification, though BSX provides purer exposure to the high-growth heart mapping and ablation market.
See full analysis → - COLDEWEdwards Lifesciences
COLDER — facing significant pressure in its core TAVR market and recently lowered guidance, whereas BSX is accelerating into new categories.
See full analysis →
- BSX-3.8%
- MDT+11.9%
- ABT+7.5%
- EW+6.6%
Analyst price target
Consensus average of 22 analysts · median 50.00
Source: StockAnalysis.com · updated 2026-10-30
AI-generated analysis for informational purposes only. Not financial advice.